Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.35 |
| ▸ | ADH1A | P07327 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19910925 | 1.00 | ADH1B (0.35) | ADH1BADH1CADH1ACYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL19895467 | 0.97 | ADH1B (0.33) | ADH1BADH1CADH1ACYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL19895466 | 0.97 | ADH1B (0.33) | ADH1BADH1CADH1ACYP2D6CYP2C19 | |
| SCHEMBL13995775 | 0.80 | — | — | |
| SCHEMBL19576713 | 0.80 | — | — | |
| SCHEMBL13995863 | 0.80 | — | — | |
| SCHEMBL24972209 | 0.75 | ADH1B (0.32) | ADH1BADH1CADH1ACYP2D6CYP2C19 | |
| SCHEMBL20099443 | 0.75 | TSHR (0.35) | — | |
| SCHEMBL23665103 | 0.75 | — | — | |
| SCHEMBL21141281 | 0.73 | ADH1B (0.35) | ADH1BADH1CADH1ACYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3508487-B1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2021-06-16 | — | — | EP | disclosed |
| US-20200290950-A1 | ALKAMIDE COMPOUNDS AND USES THEREOF | NORTH CAROLINA STATE UNIVERSITY | 2020-09-17 | — | — | US | disclosed |
| EP-3508487-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20190015374-A1 | Fumarate Ester Pharmaceutical Compositions | BANNER LIFE SCIENCES LLC | 2019-01-17 | — | — | US | disclosed |
| EP-1255738-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290950-A1 | ALKAMIDE COMPOUNDS AND USES THEREOF | ALK, ENPP2, CYSLTR2 | ADH1B 3025/4885ADH1C 3221/4885ADH1A 2070/4885 |
| US-20190015374-A1 | Fumarate Ester Pharmaceutical Compositions | FH, FAH, SDHB | ADH1B 175/4885ADH1C 710/4885ADH1A 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.